Orthocell's Remplir Device Aids 23 Surgeries in Ukraine

MT Newswires Live
Mar 18

Orthocell (ASX:OCC) reported that its Remplir nerve repair device has been successfully used in 23 surgeries on injured Ukrainian soldiers, following a humanitarian delivery in April 2025, according to a Wednesday Australian bourse filing.

The device was used in both primary and secondary nerve repairs, with surgeons reporting positive feedback on its portability, ease of use, and suitability for major trauma in defense settings, per the filing.

The company plans to continue monitoring patient outcomes and collecting clinical data to support future engagement with defense organizations globally, the filing added.

The company's shares rose 2% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10